[Skip to Navigation]
April 2014

Coverage With Evidence Development: What to Consider

Author Affiliations
  • 1Center for Alzheimer’s Care, Imaging, and Research, Department of Neurology, University of Utah, Salt Lake City
  • 2Clinical Research Compliance and Education, University of Utah, Salt Lake City
  • 3Department of Neurology, University of Utah, Salt Lake City
  • 4Department of Radiology, University of Utah, Salt Lake City
  • 5Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, Utah
JAMA Neurol. 2014;71(4):399-400. doi:10.1001/jamaneurol.2013.5812

Coverage with evidence development (CED) is a reimbursement mechanism the Centers for Medicare and Medicaid Services (CMS) is increasingly using for new technologies.1 The September 2013 CMS coverage decision for amyloid positron-emission tomography (PET) indicated that amyloid PET imaging under most circumstances will not be reimbursed. Reimbursement is possible only through CED in a CMS-approved study. Thus, many neurologists for the first time will face the decision of whether to participate in CED. We hope that sharing our experience with CED for use of 18fluorodeoxyglucose (FDG)-PET in the treatment of mild cognitive impairment through the Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) Study (eAppendix 1 in Supplement) will be instructive.

Add or change institution